Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Via Megan McArdle, Derek Lowe blogs today about an entire field of pharmaceutical research revolving around PPAR ligands that pretty much went nowhere and cost drug companies a bundle:

Allow me to rant for a bit, because I saw yet another argument the other day that the big drug companies don’t do any research, no, it’s all done at universities with public funds, at which point Big Pharma just swoops in and makes off with the swag. You know the stuff. Well, I would absolutely love to have the people who hold that view explain the PPAR story to me. I really would. The drug industry poured a huge amount of time and money into both basic and applied research in that area, and they did it for years. No one has to take my word for it — ask any of the academic leaders in the field if GSK or Merck, to name just two companies, managed to make any contributions.

….Honestly, I don’t understand where these they-don’t-do-any-research folks get off. Look at the patent filings. Look at the open literature. Where on earth do you think all those molecules come from, all those research programs to fill up all those servers? There are whole scientific journals that wouldn’t exist if it weren’t for a steady stream of failed research projects. Where’s it all coming from?

I don’t doubt that Derek saw this argument somewhere, and to be honest, I don’t even begrudge him the rant. We’re all sensitive to dumb arguments in our own areas of expertise, especially if we’re really tired of hearing them.

But I’m genuinely curious: is there anyone of any stature who’s made this argument? I’ve never seen it. There are plenty of arguments about the relative size of the contributions of academic and commercial pharmaceutical research, and plenty of arguments about whether, for example, the current patent regime is the best way of incentivizing commercial research. But the basic story seems to be pretty broadly accepted: universities and the government do a lot of basic research and corporations then take that research and do the work necessary to produce actual commercial drugs that attack actual illnesses. It doesn’t always work that way (private companies do some basic research too), but I’ve never seen a serious argument that commercial pharma companies do nothing at all.

Anyway, just curious. I’m not really picking on Derek here, I guess I’ve just spent too much time lately being annoyed by the amount of time we all spend responding to the dumbest, most extreme forms of arguments, and then this one happened to pop up. But who knows? Maybe I’m wrong and JAMA and the New England Journal of Medicine are chock full of editorials telling us that commercial researchers don’t actually do anything. If so, I’ll stand corrected.

POSTSCRIPT: Of course, in the political world lots of influential people really do make dumb, extreme arguments on a regular basis. And since they’re influential, they have to be responded to. But I still wonder if maybe we respond to them too much. Or maybe in the wrong way. Or something.

AN IMPORTANT UPDATE ON MOTHER JONES' FINANCES

We need to start being more upfront about how hard it is keeping a newsroom like Mother Jones afloat these days.

Because it is, and because we're fresh off finishing a fiscal year, on June 30, that came up a bit short of where we needed to be. And this next one simply has to be a year of growth—particularly for donations from online readers to help counter the brutal economics of journalism right now.

Straight up: We need this pitch, what you're reading right now, to start earning significantly more donations than normal. We need people who care enough about Mother Jones’ journalism to be reading a blurb like this to decide to pitch in and support it if you can right now.

Urgent, for sure. But it's not all doom and gloom!

Because over the challenging last year, and thanks to feedback from readers, we've started to see a better way to go about asking you to support our work: Level-headedly communicating the urgency of hitting our fundraising goals, being transparent about our finances, challenges, and opportunities, and explaining how being funded primarily by donations big and small, from ordinary (and extraordinary!) people like you, is the thing that lets us do the type of journalism you look to Mother Jones for—that is so very much needed right now.

And it's really been resonating with folks! Thankfully. Because corporations, powerful people with deep pockets, and market forces will never sustain the type of journalism Mother Jones exists to do. Only people like you will.

There's more about our finances in "News Never Pays," or "It's Not a Crisis. This Is the New Normal," and we'll have details about the year ahead for you soon. But we already know this: The fundraising for our next deadline, $350,000 by the time September 30 rolls around, has to start now, and it has to be stronger than normal so that we don't fall behind and risk coming up short again.

Please consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

—Monika Bauerlein, CEO, and Brian Hiatt, Online Membership Director

payment methods

AN IMPORTANT UPDATE ON MOTHER JONES' FINANCES

We need to start being more upfront about how hard it is keeping a newsroom like Mother Jones afloat these days.

Because it is, and because we're fresh off finishing a fiscal year, on June 30, that came up a bit short of where we needed to be. And this next one simply has to be a year of growth—particularly for donations from online readers to help counter the brutal economics of journalism right now.

Straight up: We need this pitch, what you're reading right now, to start earning significantly more donations than normal. We need people who care enough about Mother Jones’ journalism to be reading a blurb like this to decide to pitch in and support it if you can right now.

Urgent, for sure. But it's not all doom and gloom!

Because over the challenging last year, and thanks to feedback from readers, we've started to see a better way to go about asking you to support our work: Level-headedly communicating the urgency of hitting our fundraising goals, being transparent about our finances, challenges, and opportunities, and explaining how being funded primarily by donations big and small, from ordinary (and extraordinary!) people like you, is the thing that lets us do the type of journalism you look to Mother Jones for—that is so very much needed right now.

And it's really been resonating with folks! Thankfully. Because corporations, powerful people with deep pockets, and market forces will never sustain the type of journalism Mother Jones exists to do. Only people like you will.

There's more about our finances in "News Never Pays," or "It's Not a Crisis. This Is the New Normal," and we'll have details about the year ahead for you soon. But we already know this: The fundraising for our next deadline, $350,000 by the time September 30 rolls around, has to start now, and it has to be stronger than normal so that we don't fall behind and risk coming up short again.

Please consider pitching in before moving on to whatever it is you're about to do next. We really need to see if we'll be able to raise more with this real estate on a daily basis than we have been, so we're hoping to see a promising start.

—Monika Bauerlein, CEO, and Brian Hiatt, Online Membership Director

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate